Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$3.2B
126M shares
52-week range
$18.77 – $26.51
88% from low
Sector
SERVICES-HEALTH SERVICES
Exchange
NASDAQ
CS
Borrow rate
0.30%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $657.6M | $786.4M | $817.1M | $966.2M | $1.36B | $1.66B | $1.74B | $2.12B |
| Cost of revenue | $601.1M | $717.9M | $734.5M | $902.6M | $1.22B | $1.50B | $1.56B | $1.91B |
| Gross profit | $56.5M | $68.5M | $82.6M | $63.7M | $134.8M | $161.5M | $176.9M | $209.4M |
| Gross margin | 8.6% | 8.7% | 10.1% | 6.6% | 9.9% | 9.7% | 10.2% | 9.9% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $2.2M | $16.1M | $25.4M | −$217.4M | −$19.1M | $20.6M | $17.0M | $34.2M |
| EBITDA | $3.2M | $17.5M | $27.2M | −$215.0M | −$14.0M | $35.6M | $35.1M | $53.8M |
| Net income | −$3.0M | $8.2M | $31.2M | −$188.2M | −$8.6M | $23.1M | $14.4M | $22.9M |
| Net margin | -0.5% | 1.0% | 3.8% | -19.5% | -0.6% | 1.4% | 0.8% | 1.1% |
| EPS (diluted) | -0.03 | 0.08 | 0.30 | -1.77 | -0.08 | 0.19 | 0.11 | 0.18 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.4B | $0.24 | $0.22–$0.27 | 9 |
| 2027 | $2.7B | $0.41 | $0.40–$0.43 | 9 |
| 2028 | $3.0B | $0.58 | $0.50–$0.74 | 5 |
| 2029 | $3.1B | $0.73 | $0.71–$0.76 | 1 |
Forward consensus · source: Financial Modeling Prep
Privia Health Group Inc is one of the physician enablement companies in the United States with a presence in around 24 states and the District of Columbia. The group builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. It collaborates with medical groups, health plans, and health systems to optimize approximately 1,300+ physician practices, improve the patient experience for over 5.8+ million patients, and reward around 5,300+ physicians and practitioners for delivering high-value care.
www.priviahealth.comNo one on the platform currently holds PRVA.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 776,500 | $16.0M |
| Bridgewater Associatesas of 2026-03-31 | 237,948 | $4.9M |
No one on the platform has traded PRVA yet.
| $3.7B |
| — |
| LIVNLivaNova PLC | $83.06 | -0.44% | $4.6B | — |
| NVSTEnvista Holdings Corp | $27.02 | +0.22% | $4.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
Trading at 204.7× earnings vs its 132.3× historical median P/E.
Fair value ≈ $16.52 · price $25.55 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$HIMS prices in about 23.9% fcf growth every year, not impossible but is quite high. done at wacc of 7,5% though.. $CVS $CI $RDNT $PRVA
View on StockTwits ↗$PRVA https://www.investing.com/news/earnings/privia-health-earnings-on-deck-as-analysts-eye-provider-expansion-93CH-4664569
View on StockTwits ↗Privia Health Group Q1 Earnings Call Highlights $PRVA https://www.marketbeat.com/instant-alerts/privia-health-group-q1-earnings-call-highli
View on StockTwits ↗$PRVA Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.02 down -33.33% YoY • Reported revenue of $603.85M up 25.78% YoY • Privia Health reiterated its full-year 2026 outlook for most metrics, but raised its guidance range for Attributed Lives to 1,600,000 - 1,625,000. The company expects approximately 80% of Adjusted EBITDA to convert to free cash flow.
View on StockTwits ↗$PRVA Share Price: $24.30 Contract Selected: Nov 20, 2026 $25 Calls Buy Zone: $1.19 – $1.47 Target Zone: $2.10 – $2.57 Potential Upside: 67% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
View on StockTwits ↗$PRVA Current Stock Price: $24.42 Contracts to trade: $25.0 PRVA May 15 2026 Call Entry: $0.41 Exit: $0.54 ROI: 30% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$PRVA Privia Health price target raised to $35 from $33 at JPMorgan JPMorgan raised the firm's price target on Privia Health to $35 from $33 and keeps an Overweight rating on the shares. The firm views the company's Q4 report as solid. It increased estimates post the print.
View on StockTwits ↗$PRVA: Privia Health beats by $0.22, beats on revs; guides FY26 revs above consensus https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20260226060445PRVA&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page
View on StockTwits ↗$PRVA Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $0.07 up 75.00% YoY • Reported revenue of $541.17M up 17.42% YoY • Privia Health expects 2026 GAAP Revenue between $2.35B and $2.45B, and Adjusted EBITDA between $145M and $155M, reflecting approximately 20% growth at midpoint.
View on StockTwits ↗$PRVA Healthcare analytics platform benefiting from value-based care adoption.
View on StockTwits ↗$PRVA not sure why the high valuation. Can anyone explain? EV of $2.4B and adjusted EBITDA of $97M, don’t understand why it’s a 25X business? Understand their risk based agreements are not the core of their earnings but still don’t get it.
View on StockTwits ↗$PRVA Bullish Engulfing Candlestick Pattern Formed at Downtrend near Support Level
View on StockTwits ↗$PRVA Current Stock Price: $24.29 Contracts to trade: $25 PRVA Jan 16 2026 Call Entry: $0.45 Exit: $0.59 ROI: 30% Hold ~24 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$PRVA The environment increasingly favors disciplined operators instead of aggressive storytellers. Margin trajectory needs to confirm that scale creates leverage, not dilution. Overextension would degrade optionality during downturns. Patience is reasonable — but it must be earned.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.